Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress.

Epoxyeicosatrienoic acids (EETs) are active metabolites of arachidonic acid that are inactivated by soluble epoxide hydrolase enzyme (sEH) to dihydroxyeicosatrienoic acid. EETs are known to render cardioprotection against ischemia reperfusion (IR) injury by maintaining mitochondrial function. We investigated the effect of a novel sEH inhibitor (sEHi) in limiting IR injury. Mouse hearts were perfused in Langendorff mode for 40 min and subjected to 20 min of global no-flow ischemia followed by 40 min of reperfusion. Hearts were perfused with 0.0, 0.1, 1.0 and 10.0 µmol·L(-1) of the sEHi N-(2-chloro-4-methanesulfonyl-benzyl)-6-(2,2,2-trifluoro-ethoxy)-nicotinamide (BI00611953). Inhibition of sEH by BI00611953 significantly improved postischemic left-ventricular-developed pressure and reduced infarct size following IR compared with control hearts, and similar to hearts perfused with 11,12-EETs (1 µmol·L(-1)) and sEH(-/-) mice. Perfusion with the putative EET receptor antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE, 10 µmol·L(-1)), or the plasma membrane K(ATP) channels (pmK(ATP)) inhibitor (glibenclamide, 10 µmol·L(-1)) abolished the improved recovery by BI00611953 (1 µmol·L(-1)). Mechanistic studies in H9c2 cells demonstrated that BI0611953 decreased ROS generation, caspase-3 activity, proteasome activity, increased HIF-1∝ DNA binding, and delayed the loss of mitochondrial membrane potential (ΔΨ(m)) caused by anoxia-reoxygenation. Together, our data demonstrate that the novel sEHi BI00611953, a nicotinamide-based compound, provides significant cardioprotection against ischemia reperfusion injury.

[1]  B. Baban,et al.  Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats. , 2013, Clinical science.

[2]  P. Light,et al.  Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response , 2013, Cell Death and Disease.

[3]  A. Gomes,et al.  Proteomic analysis of hearts from Akita mice suggests that increases in soluble epoxide hydrolase and antioxidative programming are key changes in early stages of diabetic cardiomyopathy. , 2013, Journal of proteome research.

[4]  J. Seubert,et al.  Sonodynamic and photodynamic mechanisms of action of the novel hypocrellin sonosensitizer, SL017: mitochondrial cell death is attenuated by 11, 12-epoxyeicosatrienoic acid , 2011, Investigational New Drugs.

[5]  J. Falck,et al.  Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury , 2011, British journal of pharmacology.

[6]  S. Cases,et al.  1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. , 2011, Bioorganic & medicinal chemistry letters.

[7]  J. Aragonés,et al.  Mitochondrial reprogramming through cardiac oxygen sensors in ischaemic heart disease. , 2010, Cardiovascular research.

[8]  N. Farrow,et al.  Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase. , 2010, Bioorganic & medicinal chemistry letters.

[9]  S. Hwang,et al.  Inhibition of Soluble Epoxide Hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid Is Protective Against Ischemia–Reperfusion Injury , 2010, Journal of cardiovascular pharmacology.

[10]  P. Pasdois,et al.  The role of the mitochondrial permeability transition pore in heart disease. , 2009, Biochimica et biophysica acta.

[11]  I. Muegge,et al.  Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. , 2009, Bioorganic & medicinal chemistry letters.

[12]  J. Berger,et al.  Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[13]  B. Hammock,et al.  14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. , 2009, Journal of medicinal chemistry.

[14]  J. Falck,et al.  Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function. , 2009, Cardiovascular research.

[15]  E. Jacobs,et al.  Protective actions of epoxyeicosatrienoic acid: dual targeting of cardiovascular PI3K and KATP channels. , 2009, Journal of molecular and cellular cardiology.

[16]  J. Falck,et al.  Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. , 2009, Journal of molecular and cellular cardiology.

[17]  M. Arand,et al.  Mammalian epoxide hydrolases in xenobiotic metabolism and signalling , 2009, Archives of Toxicology.

[18]  G. Semenza.  Regulation of oxygen homeostasis by hypoxia-inducible factor 1. , 2009, Physiology.

[19]  N. Danial,et al.  Bad targets the permeability transition pore independent of Bax or Bak to switch between Ca2+-dependent cell survival and death. , 2009, Molecular cell.

[20]  J. Iliff,et al.  Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo. , 2008, American journal of physiology. Heart and circulatory physiology.

[21]  J. Falck,et al.  Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart. , 2008, American journal of physiology. Heart and circulatory physiology.

[22]  Martin Vingron,et al.  Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease , 2008, Nature Genetics.

[23]  Z. Bosnjak,et al.  Role of sarcolemmal ATP-sensitive potassium channel in oxidative stress-induced apoptosis: mitochondrial connection. , 2008, American journal of physiology. Heart and circulatory physiology.

[24]  R. Noppens,et al.  Soluble Epoxide Hydrolase: A Novel Therapeutic Target in Stroke , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[25]  B. Hammock,et al.  The soluble epoxide hydrolase as a pharmaceutical target for hypertension. , 2007, Journal of cardiovascular pharmacology.

[26]  J. Falck,et al.  Mechanisms by which epoxyeicosatrienoic acids (EETs) elicit cardioprotection in rat hearts. , 2007, Journal of molecular and cellular cardiology.

[27]  B. Hammock,et al.  Compensatory Mechanism for Homeostatic Blood Pressure Regulation in Ephx2 Gene-disrupted Mice* , 2007, Journal of Biological Chemistry.

[28]  J. Falck,et al.  Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function , 2006, Circulation research.

[29]  B. Hammock,et al.  Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. , 2005, Annual review of pharmacology and toxicology.

[30]  W. Giles,et al.  Plasma‐membrane KATP channel‐mediated cardioprotection involves posthypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  J. Foley,et al.  Enhanced Postischemic Functional Recovery in CYP2J2 Transgenic Hearts Involves Mitochondrial ATP-Sensitive K+ Channels and p42/p44 MAPK Pathway , 2004, Circulation research.

[32]  B. Hammock,et al.  Epoxide hydrolases in the rat epididymis: possible roles in xenobiotic and endogenous fatty acid metabolism. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[33]  S. Seino,et al.  Role of sarcolemmal KATP channels in cardioprotection against ischemia/reperfusion injury in mice , 2002 .

[34]  T. Lu,et al.  Activation of ATP‐sensitive K+ channels by epoxyeicosatrienoic acids in rat cardiac ventricular myocytes , 2001, The Journal of physiology.

[35]  S. Seino,et al.  Functional Roles of Cardiac and Vascular ATP-Sensitive Potassium Channels Clarified by Kir6.2-Knockout Mice , 2001, Circulation research.

[36]  Christophe Person,et al.  Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells , 1998, Nature.

[37]  G. Gross,et al.  Activation of cardiac KATP channels: an endogenous protective mechanism during repetitive ischemia. , 1993, The American journal of physiology.

[38]  D. Zeldin,et al.  Resolution of dihydroxyeicosanoates and of dihydroxyeicosatrienoates by chiral phase chromatography. , 1992, Analytical biochemistry.

[39]  A. Noma,et al.  ATP-regulated K+ channels in cardiac muscle , 1983, Nature.

[40]  D. Brocks,et al.  Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model. , 2009, Journal of molecular and cellular cardiology.

[41]  S. Seino,et al.  Role of ATP-sensitive K+ channels in electrophysiological alterations during myocardial ischemia: a study using Kir6.2-null mice. , 2005, American journal of physiology. Heart and circulatory physiology.

[42]  Xiang Fang,et al.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. , 2004, Progress in lipid research.

[43]  R. Roman,et al.  P-450 metabolites of arachidonic acid in the control of cardiovascular function. , 2002, Physiological reviews.